37 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Article Searches
2 Top Growth Stocks to Buy With $1,000 Right Now https://www.fool.com/investing/2024/02/18/2-top-growth-stocks-to-buy-with-1000-right-now/?source=iedfolrf0000001 Feb 17, 2024 - Even a modest starting investment in the right stocks could pay off in the years ahead.
3 Stocks to Buy Before 2024 That Can Set You Up For Life https://www.fool.com/investing/2023/12/14/3-stocks-to-buy-before-2024-that-can-set-you-up/?source=iedfolrf0000001 Dec 14, 2023 - These stocks are still relatively cheap, but don't expect them to stay that way for long.
2 No-Brainer Biotech Stocks to Buy Right Now https://www.fool.com/investing/2024/02/21/2-no-brainer-biotech-stocks-to-buy-right-now/?source=iedfolrf0000001 Feb 21, 2024 - These stocks are used to beating the market.
EyePoint (EYPT) Surges 178% on Upbeat Phase II Eye Disease Data https://www.zacks.com/stock/news/2193528/eyepoint-eypt-surges-178-on-upbeat-phase-ii-eye-disease-data?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193528 Dec 05, 2023 - EyePoint (EYPT) announces positive top-line data from the phase II study of its investigational candidate, EYP-1901, in the treatment of wet age-related macular degeneration. The stock rallies 178%.
Sanofi (SNY) Posts Upbeat Long-Term Outlook, Enhances R&D Focus https://www.zacks.com/stock/news/2195113/sanofi-sny-posts-upbeat-long-term-outlook-enhances-r-d-focus?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2195113 Dec 07, 2023 - Sanofi (SNY) aims to generate annual sales of over 10 billion euros by 2030, driven by recently launched and potential new products. It intends to enhance R&D focus to become a market leader in immunology.
Top Analyst Reports for Chevron, SAP & United Parcel Service https://www.zacks.com/commentary/2195370/top-analyst-reports-for-chevron-sap-united-parcel-service?cid=CS-ZC-FT-research_daily-2195370 Dec 08, 2023 - Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation (CVX), SAP SE (SAP) and United Parcel Service, Inc. (UPS).
Regeneron (REGN) Posts Positive Data on Blood Cancer Candidate https://www.zacks.com/stock/news/2195671/regeneron-regn-posts-positive-data-on-blood-cancer-candidate?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2195671 Dec 08, 2023 - Regeneron's (REGN) multiple myeloma candidate demonstrates strong rates and depth of response in pre-treated patients.
Top 5 Momentum Picks for January After a Fabulous 2023 https://www.zacks.com/stock/news/2204856/top-5-momentum-picks-for-january-after-a-fabulous-2023?cid=CS-ZC-FT-analyst_blog|investment_ideas-2204856 Jan 03, 2024 - We have narrowed our search to five large-cap stocks that have strong momentum for January. These are BGNE, SHOP, REGN, SPLK and CASY.
Earnings Estimates Moving Higher for Regeneron (REGN): Time to Buy? https://www.zacks.com/stock/news/2205196/earnings-estimates-moving-higher-for-regeneron-regn-time-to-buy?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_8-2205196 Jan 03, 2024 - Regeneron (REGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Merck (MRK) Keytruda Ok'd by FDA for Expanded Cervical Cancer Use https://www.zacks.com/stock/news/2210152/merck-mrk-keytruda-ok-d-by-fda-for-expanded-cervical-cancer-use?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2210152 Jan 15, 2024 - FDA approves Merck's (MRK) Keytruda plus chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer based on data from the phase KEYNOTE-A18 study.

Pages: 1234

Page 1>